StockData
Cocrystal Pharma, Inc. logo

Cocrystal Pharma, Inc. (COCP) stock

COCPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$0.98−0.00 (-0.24%)

Close on Nov 16, 2026Market cap $18.83MP/E –Yield –

Cocrystal Pharma r&d expenses

Research and development expenses are spending on new products and technology.

Cocrystal Pharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $6.09M, down 21.6% year over year. For fiscal 2025 it was $5.06M, down 59.7% from the year before. Over ten years it grew -20.0% a year on average. The highest annual figure on record is $101.68M in fiscal 2016.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$5.06M-59.7%
FY2024Dec 31, 2024$12.54M-17.4%
FY2023Dec 31, 2023$15.17M+22.4%
FY2022Dec 31, 2022$12.39M+40.9%
FY2021Dec 31, 2021$8.79M+45.7%
FY2020Dec 31, 2020$6.03M+50.7%
FY2019Dec 31, 2019$4.00M-14.2%
FY2018Dec 31, 2018$4.67M-19.8%
FY2017Dec 31, 2017$5.82M-94.3%
FY2016Dec 31, 2016$101.68M+115.1%
FY2015Dec 31, 2015$47.26M+1060.9%
FY2014Dec 31, 2014$4.07M+5.4%
FY2013Dec 31, 2013$3.86M+689.2%
FY2012Dec 31, 2012$489.35K+15.6%
FY2011Dec 31, 2011$423.18K+75.7%
FY2010Dec 31, 2010$240.87K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.14M+90.9%
Q1 FY2026Mar 31, 2026$1.37M+0.8%
Q4 FY2025Dec 31, 2025$1.62M-20.5%
Q3 FY2025Sep 30, 2025$954.00K-70.6%
Q2 FY2025Jun 30, 2025$1.12M-74.0%
Q1 FY2025Mar 31, 2025$1.36M-53.9%
Q4 FY2024Dec 31, 2024$2.04M-52.3%
Q3 FY2024Sep 30, 2024$3.24M-22.7%
Q2 FY2024Jun 30, 2024$4.31M+53.8%
Q1 FY2024Mar 31, 2024$2.95M-24.5%
Q4 FY2023Dec 31, 2023$4.27M+29.8%
Q3 FY2023Sep 30, 2023$4.19M+8.3%
Q2 FY2023Jun 30, 2023$2.80M+18.6%
Q1 FY2023Mar 31, 2023$3.91M+36.0%
Q4 FY2022Dec 31, 2022$3.29M+20.3%
Q3 FY2022Sep 30, 2022$3.87M+83.9%
Q2 FY2022Jun 30, 2022$2.36M-7.7%
Q1 FY2022Mar 31, 2022$2.87M+82.1%
Q4 FY2021Dec 31, 2021$2.73M+291.5%
Q3 FY2021Sep 30, 2021$2.11M+1.3%
Q2 FY2021Jun 30, 2021$2.56M+29.4%
Q1 FY2021Mar 31, 2021$1.58M+22.9%
Q4 FY2020Dec 31, 2020$698.00K-27.1%
Q3 FY2020Sep 30, 2020$2.08M+92.9%
Q2 FY2020Jun 30, 2020$1.98M+81.1%
Q1 FY2020Mar 31, 2020$1.28M+46.1%
Q4 FY2019Dec 31, 2019$958.00K-20.4%
Q3 FY2019Sep 30, 2019$1.08M-26.6%
Q2 FY2019Jun 30, 2019$1.09M-2.5%
Q1 FY2019Mar 31, 2019$878.00K+0.1%
Q4 FY2018Dec 31, 2018$1.20M+9.1%
Q3 FY2018Sep 30, 2018$1.47M+5.3%
Q2 FY2018Jun 30, 2018$1.12M-19.7%
Q1 FY2018Mar 31, 2018$877.00K-57.7%
Q4 FY2017Dec 31, 2017$1.10M-98.8%
Q3 FY2017Sep 30, 2017$1.39M-33.4%
Q2 FY2017Jun 30, 2017$1.39M–
Q1 FY2017Mar 31, 2017$2.07M–
Q4 FY2016Dec 31, 2016$93.88M–
Q3 FY2016Sep 30, 2016$2.09M–

More Cocrystal Pharma figures

See a number that looks wrong?